SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy

Cancer Research

Volumn 73, Issue 23, 2013, Pages 6951-6962

  Jung, Yewon ^a   Abdel Fatah, Tarek M A ^b   Chan, Stephen Y T ^b   Nolan, Christopher C ^b   Green, Andrew R ^b   Ellis, Ian O ^b   Li, Lili ^c   Huang, Baiqu ^c   Lu, Jun ^c   Xu, Bing ^a   Chen, Longxin ^d   Ma, Runlin Z ^d   Zhang, Min ^e   Wang, Jingru ^e   Wu, ZhengSheng ^f   Zhu, Tao ^e   Perry, Jo K ^a   Lobie, Peter E ^g,h   Liu, Dong Xu ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NORTHEAST NORMAL UNIVERSITY   (China)

^d INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^e UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^f ANHUI MEDICAL UNIVERSITY   (China)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC REGULATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; RNA INTERFERENCE; SHON GENE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84890285744     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0982     Document Type: Article

References (50)

1. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011;11:597-608.
2. Baumgarten SC, Frasor J. Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 2012;26:360-71.
3. Barnes CJ, Vadlamudi RK, Kumar R. Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci 2004;61:281-91.
4. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86.
5. Jagannathan V, Robinson-Rechavi M. Meta-analysis of estrogen response in MCF-7 distinguishes early target genes involved in signaling and cell proliferation from later target genes involved in cell cycle and DNA repair. BMC Syst Biol 2011;5:138.
6. Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology 2009;23:133-42.
7. Giuliano M, Schifp R, Osborne CK, Trivedi MV. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 2011;20 Suppl 3:S42-9.
8. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43.
9. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-47.
10. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003;22:7316-39.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
12. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le QJ, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010;103:668-75.
13. Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 2012;226:97-107.
14. Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010;119:53-61.
15. Clamp M, Fry B, Kamal M, Xie X, Cuff J, Lin MF, et al. Distinguishing protein-coding and noncoding genes in the human genome. Proc Natl Acad Sci U S A 2007;104:19428-33.
16. Stahl PD, Wainszelbaum MJ. Human-specific genes may offer a unique window into human cell signaling. Sci Signal 2009;2:e59.
17. Nakamura T, Hillova J, Mariage-Samson R, Onno M, Huebner K, Cannizzaro LA, et al. A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells. Oncogene 1992;7:733-41.
18. Pei L, Peng Y, Yang Y, Ling XB, Van Eyndhoven WG, Nguyen KC, et al. PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. Cancer Res 2002;62:5420-4.
19. Wainszelbaum MJ, Charron AJ, Kong C, Kirkpatrick DS, Srikanth P, Barbieri MA, et al. The hominoid-specific oncogene TBC1D3 activates Ras and modulates epidermal growth factor receptor signaling and trafficking. J Biol Chem 2008;283:13233-42.
20. Wainszelbaum MJ, Liu J, Kong C, Srikanth P, Samovski D, Su X, et al. TBC1D3, a hominoid-specific gene, delays IRS-1 degradation and promotes insulin signaling by modulating p70 S6 kinase activity. PLoS ONE 2012;7:e31225.
21. Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, et al. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res 2003;13:2265-70.
22. Liu DX, Lobie PE. Transcriptional activation of p53 by Pitx1. Cell Death Differ 2007;14:1893-907.
23. Zhang X, Zhu T, Chen Y, Mertani HC, Lee KO, Lobie PE. Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem 2003;278:7580-90.
24. Maitra R, Porter MA, Huang S, Gilmour BP. Inhibition of NF-κB by the natural product Withaferin A in cellular models of Cystic Fibrosis inflammation. J Inflamm 2009;6:15.
25. Green AR, Burney C, Granger CJ, Paish EC, El-Sheikh S, Rakha EA, et al. The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat 2008;110:427-37.
26. Elsheikh S, Green AR, Aleskandarany MA, Grainge M, Paish CE, Lambros MB, et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008;109:325-35.
27. Bendtsen JD, Nielsen H, von HG, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 2004;340:783-95.
28. Real PJ, Cao Y, Wang R, Nikolovska-Coleska Z, Sanz-Ortiz J, Wang S, et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 2004;64:7947-53.
29. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-5.
30. Hoshi S, Goto M, Koyama N, Nomoto K, Tanaka H. Regulation of vascular smooth muscle cell proliferation by nuclear factor-κB and its inhibitor, I-κB. J Biol Chem 2000;275:883-9.
31. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: involvement of nuclear factor κB and mitochondria pathways. Clin Cancer Res 2006;12:950-60.
32. Zhou Z, Qiao JX, Shetty A, Wu G, Huang Y, Davidson NE, et al. Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cell Mol Life Sci. 2013 Jun 5. [Epub ahead of print].
33. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 2006;7:497-508.
34. Cato AC, Nestl A, Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 2002;2002:re9.
35. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006;13 Suppl 1:S15-24.
36. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal 2011;23:1515-27.
37. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-κB by the Akt/PKB kinase. Curr Biol 1999;9:601-4.
38. Mortenson MM, Galante JG, Gilad O, Schlieman MG, Virudachalam S, Kung HJ, et al. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem 2007;102:1171-9.
39. de MD, Mustapha S, Greenberg AH, Kirshenbaum LA. Bcl-2 activates the transcription factor NFκB through the degradation of the cytoplasmic inhibitor IκBα. J Biol Chem 1998;273:23946-51.
40. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor κ B and its significance in prostate cancer. Oncogene 2001;20:7342-51.
41. Stiles BL. PI-3-K and AKT: Onto the mitochondria. Adv Drug Deliv Rev 2009;61:1276-82.
42. Marchiò C, Reis-Filho JS. Molecular diagnosis in breast cancer. Diagn Mol Pathol 2008;14:202-13.
43. Wang Z, Dahiya S, Provencher H, Muir B, Carney E, Coser K, et al. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clin Cancer Res 2007;13:6327-34.
44. Rochaix P, Krajewski S, Reed JC, Bonnet F, Voigt JJ, Brousset P. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol 1999;187:410-5.
45. Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008;8:153.
46. Martinez-Arribas F, Alvarez T, Del VG, Martin-Garabato E, Nunez-Villar MJ, Lucas R, et al. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res 2007;27:219-22.
47. Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R. BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J 2010;24:2040-55.
48. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, et al. AKT activation predicts outcomein breast cancer patients treated with tamoxifen. J Pathol 2005;207:139-46.
49. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002;86:540-5.
50. Planque N. Nuclear trafficking of secreted factors and cell-surface receptors: new pathways to regulate cell proliferation and differentiation, and involvement in cancers. Cell Commun Signal 2006;4:7.